PubMed Health⌕ Search

Biomedical subjects

J A Carruth

Publications and source records attributed to J A Carruth.

54 records · Page 3Linked to original sources
PubMed1983

Lasers in medicine.

Explore the source record for details and available documents.

Bronchial Neoplasms↗
PubMed1982

The establishment of precise physical parameters for the treatment of the port wine stain with the argon laser.

The use of the argon laser in the treatment of the port wine and stain is discussed and its mode of action and the features of a port wine stain, which may be used to predict a good response to therapy, are described. Reference is made to the wide variation in techniques used in treatment in different centers and the need to establish precise physical parameters for therapy is stressed. An attachment to the standard handpiece is described that will enable accurate power densities to be recorded.

Hemangioma↗
PubMed1979

The forehead flap: a modification in technique.

The use of the forehead flap for reconstruction within the oral cavity after tumour resection is discussed. A minor modification in technique is described. The sub-zygomatic route to the oral cavity is used and a piece of teflon or sialalastic sheet is sewn over the raw surfaces of the flap which lies within the tunnel in the cheek to facilitate retrieval of the pedicle.

Dermatologic Surgical Procedures↗
PubMed1979

Ocular complications in craniofacial fibrous dysplasia.

Three cases of craniofacial fibrous dysplasia are reported, all presenting to the ophthalmologist first. They all had ocular complications due either to direct involvement of the orbital bones or to secondary complications. Sphenoidal mucocele is added to the other complications previously reported, and accordingly a classification of the various ways that fibrous dysplasia can affect the ocular structures is proposed.

Adult↗
PubMedDate not supplied

Tubeless anesthetic technique for optimal carbon dioxide laser surgery of the larynx.

PURPOSE: To evaluate the operative conditions and safety of a tubeless technique of anesthesia for carbon dioxide laser surgery of the larynx. MATERIALS AND METHODS: This prospective study evaluated 78 consecutive procedures in 72 adult patients undergoing carbon dioxide laser microlaryngeal surgery. Anesthesia was maintained by an intravenous infusion of Propofol (ICI Pharmaceuticals, Cheshire, UK) while the patient breathed spontaneously without endotracheal intubation. RESULTS: The operative conditions were optimal in 76 of the 78 procedures providing a clear uninterrupted view of the larynx with no combustible material in the surgical field. CONCLUSIONS: This series shows the technique described to be safe without risk of combustion and provides an unobstructed view to the larynx.

Adolescent↗
PubMedDate not supplied

Lasers in medicine and surgery.

The laser produces an intense beam of pure monochromatic light. The wavelength of the light determines its effects on body tissues, and this defines the clinical role of each laser. The carbon dioxide laser is absorbed by water and it is used as a high precision, bloodless, 'light scalpel'. The blue/green argon laser beam is absorbed by structures which have its complementary colour red, and it can coagulate vessels through the without damage to clear, normal tissues. The neodymium: YAG laser is deeply absorbed in the tissues, and is used both for vessel coagulation and thermal tissue destruction. The tunable dye laser is used to photoactivate intra-tumour haematoporphyrin derivative in the treatment of many forms of malignant disease by photoradiation therapy. Lasers should only be used when they offer significant advantages over established conventional techniques, and this paper attempts to define the areas in which lasers offer these advantages.

Biomedical Engineering↗
PubMedDate not supplied

Clinical applications of photodynamic therapy.

Photodynamic therapy is a modality for the treatment of malignant disease in which a photosensitive drug is selectively absorbed or retained by malignant tissues, after intravenous injection and is then photoactivated by light of an appropriate wavelength, often produced by a laser. Over the past two decades, the combination of haematoporphyrin derivative (HPD) and then its active component dihaematoprophyrin ether (DHE), now marketed as Photofrin, plus red light at 630 nm have been used in clinical practice for the treatment of a range of tumours; some very promising results have been obtained. Several countries have approved this drug/light combination for clinical use for a number of tumours. Some second generation photosensitising agents with appropriate light sources, and with perceived advantages over Photofrin, are under investigation, and it is to be hoped that major improvements in drug/light combinations will enable photodynamic therapy to achieve its full potential in the not-too-distant future.

Antineoplastic Agents↗